Plant Name: Vicia sativa
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; FFAR1; | |
| TSHR; | |
| PTPN1; PTPN2; PTPN11; PTPN6; CDC25B; | |
| CES1; PLA2G1B; TDP1; PTGES; TERT; AKR1B10; AKR1B1; POLB; CES2; | |
| GAA; ACHE; | |
| CA2; CA12; CA1; CA9; CA14; CA7; CA4; CA6; | |
| PPARA; PPARD; PPARG; | |
| NR1H4; | |
| STAT3; | |
| APAF1; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Enzyme_unclassified | CES1 | Acyl coenzyme A:cholesterol acyltransferase | P23141 | CHEMBL2265 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PTGES | Prostaglandin E synthase | O14684 | CHEMBL5658 |
| Enzyme_unclassified | TERT | Telomerase reverse transcriptase | O14746 | CHEMBL2916 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | CES2 | Carboxylesterase 2 | O00748 | CHEMBL3180 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | PTPN11 | Protein-tyrosine phosphatase 2C | Q06124 | CHEMBL3864 |
| Protein Phosphatase | PTPN6 | Protein-tyrosine phosphatase 1C | P29350 | CHEMBL3166 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
| Transcription Factor | STAT3 | Signal transducer and activator of transcription 3 | P40763 | CHEMBL4026 |
| Unclassified | APAF1 | Apoptotic protease-activating factor 1 | O14727 | CHEMBL1795093 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.180E-13 | 7.910E-10 | CA1, CA12, CA2, CA4, CA6, CA7, CA9 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 6.650E-09 | 1.316E-05 | CA1, CA12, CA2, CA4, CA6, CA7, CA9, NR1H4, PPARA, PPARD, PPARG, PTPN1 |
| MF | GO:0140110; transcription regulator activity | GO:0004879; nuclear receptor activity | 2.242E-08 | 3.756E-05 | NR1H4, PPARA, PPARD, PPARG, STAT3 |
| BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 3.146E-07 | 2.864E-04 | FFAR1, NR1H4, PPARG, PTPN11, PTPN2, STAT3 |
| BP | GO:0008152; metabolic process | GO:0006631; fatty acid metabolic process | 6.975E-07 | 4.340E-04 | CES1, CES2, PLA2G1B, PPARA, PPARD, PPARG, PTGES |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 7.899E-07 | 4.778E-04 | CDC25B, PTPN1, PTPN11, PTPN2, PTPN6 |
| BP | GO:0009987; cellular process | GO:0060338; regulation of type I interferon-mediated signaling pathway | 1.239E-06 | 6.916E-04 | PTPN1, PTPN11, PTPN2, PTPN6 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.661E-06 | 8.413E-04 | NR1H4, PPARA, PPARD, PPARG, PTPN2 |
| BP | GO:0009987; cellular process | GO:0033277; abortive mitotic cell cycle | 3.007E-06 | 1.364E-03 | PTPN11, PTPN6 |
| MF | GO:0060089; molecular transducer activity | GO:0003707; steroid hormone receptor activity | 3.399E-06 | 1.424E-03 | NR1H4, PPARA, PPARD, PPARG |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 5.668E-06 | 2.204E-03 | PLA2G1B, PPARA, PPARD, PPARG |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 6.174E-06 | 2.318E-03 | AKR1B1, APAF1, CA2, CA9, MAPT, POLB, PPARD, PPARG, PTPN1, PTPN11, TDP1, TERT |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 9.012E-06 | 3.102E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 9.012E-06 | 3.102E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 9.012E-06 | 3.102E-03 | GPBAR1, NR1H4 |
| MF | GO:0003824; catalytic activity | GO:0047374; methylumbelliferyl-acetate deacetylase activity | 9.012E-06 | 3.102E-03 | CES1, CES2 |
| BP | GO:0050896; response to stimulus | GO:0070482; response to oxygen levels | 1.047E-05 | 3.455E-03 | APAF1, POLB, PPARA, PPARD, PPARG, TERT |
| BP | GO:0009987; cellular process | GO:0030522; intracellular receptor signaling pathway | 1.296E-05 | 4.151E-03 | NR1H4, PPARA, PPARD, PPARG, STAT3 |
| BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 1.471E-05 | 4.556E-03 | AKR1B1, CA2, CA9, PLA2G1B, PPARA, PPARG, STAT3, TSHR |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 1.800E-05 | 5.298E-03 | PTPN1, PTPN2 |
| BP | GO:0050896; response to stimulus | GO:0071495; cellular response to endogenous stimulus | 1.904E-05 | 5.455E-03 | AKR1B1, APAF1, NR1H4, PLA2G1B, PPARG, PTPN11, STAT3, TSHR |
| BP | GO:0051179; localization | GO:0010891; negative regulation of sequestering of triglyceride | 2.997E-05 | 8.158E-03 | PPARA, PPARG |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.414E-19 | 5.257E-15 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.422E-15 | 4.661E-11 | CA1, CA12, CA14, CA2, CA4, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 6.889E-19 | 5.925E-17 | CA12; CA1; CA2; CA4; CA7; CA6; CA9; CA14 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.413E-05 | 9.783E-04 | PTPN1; STAT3; PTPN11; PPARA |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.766E-05 | 7.594E-04 | AKR1B10; GAA; AKR1B1 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.446E-04 | 3.108E-03 | STAT3; PTPN6; PTPN11; PTPN2 |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 2.273E-04 | 3.258E-03 | STAT3; PTPN11; PPARA |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.178E-04 | 3.258E-03 | PPARG; PPARA; PPARD |
| hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.704E-03 | 1.629E-02 | AKR1B10; AKR1B1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 4.891E-03 | 3.057E-02 | STAT3; PTPN6; PTPN11 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.222E-03 | 3.057E-02 | STAT3; PPARD |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 6.940E-04 | 8.526E-03 | CA2; CA4 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.770E-03 | 2.383E-02 | CES2; CES1 |
| hsa00561 | Glycerolipid metabolism_Homo sapiens_hsa00561 | 4.517E-03 | 3.057E-02 | AKR1B10; AKR1B1 |
| hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.348E-03 | 1.449E-02 | AKR1B10; AKR1B1 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.976E-03 | 3.057E-02 | PLA2G1B; PTGES |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 7.018E-03 | 3.772E-02 | PTPN1; PTPN6 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 6.477E-03 | 3.714E-02 | CA2; NR1H4 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; MAPT |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD; PPARG |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PPARG |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Liver cancer | C22 | TERT |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | TERT |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | STAT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | STAT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; MAPT |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TERT |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | PPARD; MAPT |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; ACHE; CA4 |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | CES1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; FFAR1; AKR1B1; PPARG |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | CES1; PPARD |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | CES1; PLA2G1B |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | CES1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1; ACHE |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | CES1; PPARD |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TERT |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; ACHE; STAT3; CDC25B |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TERT |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; FFAR1; PPARD; PPARG; PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD; PPARG |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE; PTGES; MAPT; PPARG; PPARG |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| C00-D49: Neoplasms | Prostate cancer | C61 | TERT |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; TERT |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TERT |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1 |
| C00-D49: Neoplasms | Tumors | C00-D48 | TERT |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; STAT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| I00-I99: Diseases of the circulatory system | Peripheral vascular disease | I73.9 | CES1 |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Multiple myeloma | C90 | TERT; STAT3 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PPARG |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1; AKR1B1; ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Melanoma | C43 | TERT |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | TERT; PPARG |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |